MedTrace Logo

Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia

NCT02669706 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2016-06-30

No results posted yet for this study

Summary

The main objective of this study is to assess the safety of administering intravenous (IV) pentamidine for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in adult inpatients with hematologic malignancies and stem cell transplant recipients. There will also be an assessment of patient satisfaction associated with intravenous pentamidine PJP prophylactic therapy.

Conditions

  • Hematologic Malignancy

Interventions

DRUG

Pentamidine

Pentamidine is an antimicrobial medication given for prevention and treatment of Pneumocystis pneumonia (PJP) caused by Pneumocystis jirovecii

Sponsors & Collaborators

  • University of Illinois at Chicago

    lead OTHER

Principal Investigators

  • Jennifer Anderson, PharmD · University of Illinois at Chicago

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-05-31
Completion
2016-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02669706 on ClinicalTrials.gov